¡@
:::
Á{§É¸ÕÅç±Ð¨|¥¥x
¥xÆWÁ{§É¸ÕÅç±Ð¨|°V½m¤¤¤ß(CCTTT)
±Ð¨|³¡»OÆW¾Ç³NÛ²z±Ð¨|¸ê·½¤¤¤ß(AREE)
IRB¡þEC¼f¬d·|
Áp¦X¤HÅé¸ÕÅç©eû·|(JIRB)
Áp¦XÛ²z¼f¬d¾÷¨î(c-IRB)
¥xÆWÁ{§É¬ã¨sÛ²z¼f¬d¾Ç·|(TAIRB)
°ê¤º¬ÛÃöºô¶³sµ²
½Ã¥ÍºÖ§Q³¡(MOHW)
½Ã¥ÍºÖ§Q³¡¹«~ÃĪ«ºÞ²z¸p(TFDA)
½Ã¥ÍºÖ§Q³¡Â卯¥q ¥ÍÂå¬ì§Þ±M°Ï
½Ã¥ÍºÖ§Q³¡¹«~ÃĪ«ºÞ²z¸p ÃÄ«~±M°Ï
½Ã¥ÍºÖ§Q³¡¹«~ÃĪ«ºÞ²z¸p ÂåÀø¾¹§÷±M°Ï
¦èÃÄ¡BÂåÀø¾¹§÷¤Î¤ÆùÛ«~³\¥iÃÒº[¬ÛÃö¸ê®Æ¬d¸ß
¥þ°êÃĪ«¤£¨}¤ÏÀ³³q³ø¨t²Î
¥þ°êªk³W¸ê®Æ®w
°ê®a¬ì¾Ç¤Î§Þ³N©eû·|(NSTC)
¬F©²¬ã¨s¸ê°T¨t²Î(GRB¨t²Î)
°]¹Îªk¤H°ê®a½Ã¥Í¬ã¨s°|(NHRI)
°]¹Îªk¤HÂåÃÄ«~¬dÅ礤¤ß(CDE)
¥xÆWÁ{§É¸ÕÅç¸ê°T¥¥x(Taiwan Clinical Trials)
¥xÆWÃĪ«Á{§É¸ÕÅç¸ê°Tºô
°ê¥~¬ÛÃöºô¶³sµ²
ICH (°ê»ÚÂåÃĪk³W¨ó©M·|)
SIDCER-FERCAP (¨È¤Ó¦a°ÏÛ²z¼f¬d©eû·|½×¾Â)
AAHRPP (¤HÃþ¬ã¨s«OÅ@pµe»{ÃÒ¨ó·|)
CITI Program
ClinicalTrials.gov
¡@
[
¦^¤W¶
]